Immunovant (IMVT) stock: insider trades, news & valuation
Net buying
Close · Oct 9, 2026
$30.47
+0.7% on the day
+74.3% over 12 months
52-week range $17.03 – $44.96
Share price and insider trades
IMVT closeInsider buyInsider sale
Bought, 12 months$350M
Sold, 12 months$16.4M
Insiders buying1
Insiders selling10
Immunovant insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $350M and 10 sold $16.4M of IMVT stock on the open market.
Get emailed when insiders cluster-buy stocks like IMVT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
IMVT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $356K | 5 |
| Q3 2026 | — | 0 | $1.1M | 15 |
| Q2 2026 | — | 0 | $13.1M | 25 |
| Q1 2026 | — | 0 | $245K | 7 |
| Q4 2025 | $350M | 1 | $1.6M | 12 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit+$158MOn all tracked purchases +45.1%
Summary
Over the past 12 months, 1 Immunovant, Inc. insider reported open-market purchases totaling $350M, while 10 insiders reported sales totaling $16.4M. 10 of 64 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 9 NewSEC | Melanie GloriaCOO | Sell | 2,241217,060 held (−1%) | $32.06 | $72K | -5.0% | — |
| Oct 9 NewSEC | Jay S StoutCTO | Sell | 2,213203,128 held (−1%) | $32.06 | $71K | -5.0% | — |
| Oct 9 NewSEC | Jay S StoutCTO | Sell | 1,596201,532 held (−1%) | $32.06 | $51K | -5.0% | — |
| Oct 9 NewSEC | Tuyl Christopher VanGeneral Counsel | Sell | 1,327175,218 held (−1%) | $32.06 | $43K | -5.0% | — |
| Oct 5SEC | Eric VenkerCEO | Sell | 3,506257,075 held (−1%) | $34.11 | $120K | -10.7% | — |
| Sep 25SEC | Tuyl Christopher VanGeneral Counsel | Sell | 2,846176,545 held (−2%) | $36.36 | $103K | -16.2% | — |
| Aug 28SEC | Atul PandeDirector | Sell Plan | 1,500116,731 held (−1%) | $43.27 | $65K | -29.6% | — |
| Aug 21SEC | Melanie GloriaCOO | Sell | 3,056219,301 held (−1%) | $44.16 | $135K | -31.0% | — |
| Jul 24SEC | Tiago GiraoCFO | Sell | 6,798240,798 held (−3%) | $38.69 | $263K | -21.2% | — |
| Jul 24SEC | Jay S StoutCTO | Sell | 2,857205,341 held (−1%) | $38.69 | $111K | -21.2% | — |
| Jul 24SEC | Atul PandeDirector | Sell Plan | 1,500116,731 held (−1%) | $39.80 | $60K | -23.4% | — |
| Jul 10SEC | Melanie GloriaCOO | Sell | 1,930222,463 held (−1%) | $39.53 | $76K | -22.9% | — |
| Jul 10SEC | Jay S StoutCTO | Sell | 1,906209,779 held (−1%) | $39.53 | $75K | -22.9% | — |
| Jul 10SEC | Jay S StoutCTO | Sell | 1,399208,275 held (−1%) | $39.53 | $55K | -22.9% | — |
| Jul 10SEC | Tuyl Christopher VanGeneral Counsel | Sell | 1,143179,454 held (−1%) | $39.53 | $45K | -22.9% | — |
| Jul 10SEC | Melanie GloriaCOO | Sell | 106222,357 held (−0%) | $39.99 | $4K | -23.8% | — |
| Jul 10SEC | Jay S StoutCTO | Sell | 105209,674 held (−0%) | $39.99 | $4K | -23.8% | — |
| Jul 10SEC | Jay S StoutCTO | Sell | 77208,198 held (−0%) | $39.99 | $3K | -23.8% | — |
| Jul 10SEC | Tuyl Christopher VanGeneral Counsel | Sell | 63179,391 held (−0%) | $39.99 | $3K | -23.8% | — |
| Jul 6SEC | Eric VenkerCEO | Sell | 3,092254,280 held (−1%) | $38.48 | $119K | -20.8% | — |
| Jun 26SEC | Jay S StoutCTO | Sell | 33,277218,408 held (−13%) | $38.18 | $1.3M | -20.2% | — |
| Jun 26SEC | Tuyl Christopher VanGeneral Counsel | Sell | 14,982183,439 held (−8%) | $38.19 | $572K | -20.2% | — |
| Jun 26SEC | Melanie GloriaCOO | Sell | 14,748227,359 held (−6%) | $38.18 | $563K | -20.2% | — |
| Jun 26SEC | Tiago GiraoCFO | Sell | 10,000247,596 held (−4%) | $38.46 | $385K | -20.8% | — |
| Jun 26SEC | Jay S StoutCTO | Sell | 6,723211,685 held (−3%) | $38.94 | $262K | -21.8% | — |
| Jun 26SEC | Melanie GloriaCOO | Sell | 2,966224,393 held (−1%) | $38.95 | $116K | -21.8% | — |
| Jun 26SEC | Tuyl Christopher VanGeneral Counsel | Sell | 2,842180,597 held (−2%) | $38.96 | $111K | -21.8% | — |
| Jun 26SEC | Atul PandeDirector | Sell Plan | 1,500116,731 held (−1%) | $38.01 | $57K | -19.8% | — |
| Jun 22SEC | Tuyl Christopher VanGeneral Counsel | Sell | 2,634180,597 held (−1%) | $35.39 | $93K | -13.9% | — |
| Jun 16SEC | Atul PandeDirector | Sell Plan | 1,500116,731 held (−1%) | $34.02 | $51K | -10.4% | — |
| May 29SEC | Andrew J. FromkinDirector | Sell | 210,46874,382 held (−74%) | $33.56 | $7.1M | -9.2% | — |
| May 29SEC | Andrew J. FromkinDirector | Sell | 11,483284,850 held (−4%) | $32.64 | $375K | -6.6% | — |
| May 22SEC | Melanie GloriaCOO | Sell | 1,698242,107 held (−1%) | $32.95 | $56K | -7.5% | — |
| May 22SEC | Melanie GloriaCOO | Sell | 1,168243,805 held (−0%) | $32.15 | $38K | -5.2% | — |
| May 22SEC | Melanie GloriaCOO | Sell | 249244,973 held (−0%) | $30.41 | $8K | +0.2% | — |
| May 20SEC | Atul PandeDirector | Sell Plan | 6,000116,731 held (−5%) | $32.00 | $192K | -4.8% | — |
| May 1SEC | Robert Graham SusmanDirector | Sell Plan | 2,50236,394 held (−6%) | $27.17 | $68K | +12.1% | — |
| Apr 24SEC | Tiago GiraoCFO | Sell | 25,760247,596 held (−9%) | $29.62 | $763K | +2.9% | — |
| Apr 24SEC | Jay S StoutCTO | Sell | 2,754251,685 held (−1%) | $29.62 | $82K | +2.9% | — |
| Apr 10SEC | Melanie GloriaCOO | Sell | 8,722245,222 held (−3%) | $24.83 | $217K | +22.7% | — |
| Apr 10SEC | Jay S StoutCTO | Sell | 8,614255,957 held (−3%) | $24.83 | $214K | +22.7% | — |
| Apr 10SEC | Tuyl Christopher VanGeneral Counsel | Sell | 5,165183,231 held (−3%) | $24.83 | $128K | +22.7% | — |
| Apr 10SEC | Jay S StoutCTO | Sell | 1,518254,439 held (−1%) | $24.83 | $38K | +22.7% | — |
| Apr 3SEC | Eric VenkerCEO | Sell | 12,82020,970 held (−38%) | $24.04 | $308K | +26.7% | — |
| Apr 3SEC | Eric VenkerCEO | Sell | 1,40919,561 held (−7%) | $24.60 | $35K | +23.9% | — |
| Mar 20SEC | Tuyl Christopher VanGeneral Counsel | Sell | 2,877147,053 held (−2%) | $24.97 | $72K | +22.0% | — |
| Feb 27SEC | Melanie GloriaCOO | Sell | 1,437172,074 held (−1%) | $26.98 | $39K | +12.9% | — |
| Feb 27SEC | Melanie GloriaCOO | Sell | 942170,273 held (−1%) | $28.90 | $27K | +5.4% | — |
| Feb 27SEC | Melanie GloriaCOO | Sell | 859171,215 held (−0%) | $28.16 | $24K | +8.2% | — |
| Jan 23SEC | Jay S StoutCTO | Sell | 1,977197,634 held (−1%) | $26.03 | $51K | +17.1% | — |
| Jan 9SEC | Jay S StoutCTO | Sell | 1,148199,666 held (−1%) | $26.51 | $30K | +14.9% | — |
| Jan 9SEC | Jay S StoutCTO | Sell | 55199,611 held (−0%) | $26.92 | $1K | +13.2% | — |
| Dec 19SEC | Tuyl Christopher VanGeneral Counsel | Sell | 8,529152,214 held (−5%) | $26.78 | $228K | +13.8% | — |
| Dec 19SEC | Tuyl Christopher VanGeneral Counsel | Sell | 2,284149,930 held (−2%) | $27.38 | $63K | +11.3% | — |
| Dec 12SEC | Sciences Ltd. RoivantDirector | Buy | 16,666,666113,317,007 held (+17%) | $21.00 | $350M | +45.1% | — |
| Dec 3SEC | Andrew J. FromkinDirector | Sell Plan | 19,35188,750 held (−18%) | $23.14 | $448K | +31.7% | — |
| Dec 3SEC | Douglas J. HughesDirector | Sell Plan | 13,091122,682 held (−10%) | $23.14 | $303K | +31.7% | — |
| Dec 3SEC | Andrew J. FromkinDirector | Sell Plan | 2,89885,852 held (−3%) | $23.95 | $69K | +27.2% | — |
| Dec 3SEC | Douglas J. HughesDirector | Sell Plan | 1,909120,773 held (−2%) | $23.96 | $46K | +27.2% | — |
| Nov 21SEC | Melanie GloriaCOO | Sell | 10,251175,886 held (−6%) | $23.54 | $241K | +29.4% | — |
| Nov 21SEC | Melanie GloriaCOO | Sell | 2,375173,511 held (−1%) | $23.97 | $57K | +27.1% | — |
| Oct 24SEC | Michael GeffnerChief Medical Officer | Sell | 2,595217,958 held (−1%) | $19.03 | $49K | +60.1% | — |
| Oct 24SEC | Jay S StoutCTO | Sell | 2,520200,814 held (−1%) | $19.03 | $48K | +60.1% | — |
| Oct 10SEC | Jay S StoutCTO | Sell | 1,585203,334 held (−1%) | $16.30 | $26K | +86.9% | — |
| Oct 10SEC | Michael GeffnerChief Medical Officer | Sell | 1,272220,553 held (−1%) | $16.30 | $21K | +86.9% | — |
Insiders at Immunovant, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Sciences Ltd. RoivantDirector | $350M | — | Dec 12, 2025 | — |
| Andrew J. FromkinDirector | — | $8.0M | May 29, 2026 | — |
| Jay S StoutCTO | — | $2.4M | Oct 9, 2026 | — |
| Melanie GloriaCOO | — | $1.7M | Oct 9, 2026 | — |
| Tuyl Christopher VanGeneral Counsel | — | $1.5M | Oct 9, 2026 | — |
| Tiago GiraoCFO | — | $1.4M | Jul 24, 2026 | — |
| Eric VenkerCEO | — | $581K | Oct 5, 2026 | — |
| Atul PandeDirector | — | $425K | Aug 28, 2026 | — |
| Douglas J. HughesDirector | — | $349K | Dec 3, 2025 | — |
| Michael GeffnerChief Medical Officer | — | $70K | Oct 24, 2025 | — |
| Robert Graham SusmanDirector | — | $68K | May 1, 2026 | — |
IMVT stock: common questions
Are Immunovant, Inc. insiders buying IMVT stock?
In the past 12 months, 1 insiders reported open-market purchases of IMVT worth $350M. The latest was Director Sciences Ltd. Roivant bought $350M of IMVT at $21.00 — first open-market purchase in our records.
Are Immunovant, Inc. insiders selling IMVT stock?
10 insiders reported sales worth $16.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is IMVT's 52-week range?
Over the past year IMVT has traded between $17.03 and $44.96. It last closed at $30.47 on Oct 9, 2026.